C4 Therapeutics (CCCC) Corporate presentation summary

Strategic vision and financial position

• Aims to become a fully integrated biopharmaceutical company with a focus on best- and first-in-class protein degraders targeting validated pathways and large market opportunities.

• Cash runway expected through the end of 2028, supporting execution beyond key value inflection points.

Clinical pipeline and development milestones

• Cemsidomide, a cereblon-modulating protein degrader of IKZF1/3, is advancing in multiple myeloma (MM) with ongoing Phase 1b and Phase 2 trials, and a Phase 3 trial planned.

• Phase 1 data show cemsidomide is well-tolerated with deep and durable responses in heavily pre-treated MM patients.

• Phase 2 MOMENTUM trial in 4L+ MM is enrolling, with initial ORR data expected in 2H 2027 and potential for accelerated approval.

• Combination trials with elranatamab are ongoing, with the 75 µg dose declared safe and expansion cohorts enrolling.

Scientific rationale and competitive positioning

• IKZF1/3 are central to MM progression; cemsidomide is designed to overcome limitations of first-generation degraders and is positioned as a potential backbone therapy.

• Cemsidomide demonstrates high potency, selectivity, and a favorable dosing schedule, making it suitable for combination regimens.

• Biomarker data support synergistic activity with immune-based therapies, showing robust T-cell activation and prevention of T-cell exhaustion.